Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ndt/gfad061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The ameliorative effects of chrysin on bortezomib-induced nephrotoxicity in rats: Reduces oxidative stress, endoplasmic reticulum stress, inflammation damage, apoptotic and autophagic death.
Food Chem Toxicol
August 2024
Department of Medical Biochemistry, Faculty of Medicine, Aksaray University, Aksaray, Turkey.
Aim: Bortezomib is a proteasome inhibitor antineoplastic agent that was the first to be approved for cancer treatment. One of bortezomib's most prominent dose-limiting effects is nephrotoxicity; the underlying mechanism is believed to be oxidative stress. Chrysin is a compound found actively in honey and many plant species and stands out with its antioxidant properties.
View Article and Find Full Text PDFCarfilzomib-based antibody mediated rejection therapy in pediatric kidney transplant recipients.
Pediatr Transplant
November 2023
Divison of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Background: To date, the evidence for proteasome-inhibitor (PI) based antibody mediated rejection (AMR) therapy has been with the first-generation PI bortezomib. Results have demonstrated encouraging efficacy for early AMR with lesser efficacy for late AMR. Unfortunately, bortezomib is associated with dose-limiting adverse effects in some patients.
View Article and Find Full Text PDFThe nephrotoxicity of bortezomib: did we miss a complication after 20 years of use and multiple landmark trials?
Nephrol Dial Transplant
September 2023
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
[Renal failure in multiple myeloma: Specific management issues].
Bull Cancer
July 2024
Centre hospitalier universitaire de Saint-Louis, assistance publique-hôpitaux de Paris (APHP), université Paris Cité, service d'immuno-hématologie, 75010 Paris, France.
Article Synopsis
- Renal impairment is frequent in multiple myeloma and negatively impacts survival; the main cause of kidney injury in these patients is cast nephropathy, which happens due to the precipitation of monoclonal free light chains in renal tubules.
- Early detection and treatment of acute kidney injury are crucial to prevent it from becoming chronic, involving methods like rehydration and adjusting treatments for nephrotoxicity.
- The standard treatment involves a combination of Bortezomib and Dexamethasone, but monitoring is essential, especially in patients with existing kidney issues, requiring collaboration between hematologists and nephrologists.
Acute kidney injury in bortezomib-treated patients with multiple myeloma.
Nephrol Dial Transplant
August 2023
Nephrology Division; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Background: The nephrotoxicity of bortezomib, a proteasome inhibitor, has not yet been elucidated, although tumor lysis syndrome (TLS) associated with multiple myeloma (MM) has been reported to increase after introduction of the drug. This study compared the incidence and risk factors for acute kidney injury (AKI) and TLS in patients with MM after bortezomib-based chemotherapy to investigate drug-related nephrotoxicity.
Methods: From 2006 to 2017, 276 patients who underwent a first cycle of bortezomib-based chemotherapy for MM were identified in a single tertiary hospital.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!